Syncom Formulation (India) (BOM:524470) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524470 Syncom Formulation (India) Ltd BOM:524470
86 GF Score
Price ₹13.10
GF Value ₹20.09
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Syncom Formulation (India) Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Syncom Formulation (India) Valuation Rank Related Terms

BOM:524470
86GF Score
Syncom Formulation (India) Ltd BOM:524470
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?

Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued. The current stock price of ₹13.10 is trading 34.8% below its estimated GF Value™ of ₹20.09. GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.

Key valuation signals for BOM:524470:

  • Valuation Rank:
  • GF Value™: ₹20.09 vs. price of ₹13.10 (34.8% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syncom Formulation (India) Business Description

Other Exchanges SYNCOMF:India
Address 207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score

Get the complete analysis for BOM:524470

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹13.10
Price
₹20.09
GF Value